Healthcare DIVE August 26, 2024
A looming change to how J&J pays out discounts to 340B-eligible drugs has hospitals — and the government — crying foul.
Dive Brief:
- A major pharmaceutical company is reigniting controversy in the 340B drug discount program with an upcoming change to how it divvies out discounts for eligible drugs.
- Johnson & Johnson informed hospitals last week that it would stop giving them upfront discounts on two of its medications eligible for a discount under 340B — plaque psoriasis treatment Stelara and blood thinner Xarelto. Instead, starting Oct. 15, the drugmaker will require hospitals to pay full price for the drugs and issue them a rebate later, according to the J&J letter to hospitals reviewed by Healthcare Dive.
- The major...
Today's Sponsors
Today's Sponsor